Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer

The addition of palbociclib to maintenance anti-HER2 and endocrine therapies led to a significant improvement in progression-free survival over standard therapy, with increased toxic effects, mainly neutropenia. (Funded by Pfizer and others; PATINA ClinicalTrials.gov number, NCT02947685.).

Authors

Institutions

Publication Details

Journal
New England Journal of Medicine
Published
2026-01-28
DOI
https://doi.org/10.1056/nejmoa2511218
Citations
1
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
36.44
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer

J Lanzillotti, A DeMichele, Carrie Strand, F. Lynce et al.
1 citations
New England Journal of Medicine
Advanced Breast Cancer Therapies
36.44
article

Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer

J Lanzillotti, A DeMichele, Carrie Strand, F. Lynce, Prudence A. Francis, David Porter, Otto Metzger, J. Gligorov, María Koehler, Travis Dockter, Pierre-Etienne Heudel, L.A. Carey, Santiago Escrivá-de-Romaní, S. Goel, Carter DuFrane, E. Lim, Ariadna Holynskyj, Anna Wall, Jennifer Spoenlein, A. Prat, Luca Gianni, Prashanth Gopalakrishna, Debu Tripathy, Sibylle Loibl, Sumithra Mandrekar, Eva Ciruelos, Kathy Miller, Sagar Sardesai, Ann H. Partridge, Xavier Gonzàlez Farré, Sherene Loi, Suzette Delaloge, Eric Gauthier, Matthew Goetz, Ines Vaz-Luis, Cynthia Huang Bartlett, Daniel G. Stover, Eric P. Winer
article en
1 citations

Abstract

The addition of palbociclib to maintenance anti-HER2 and endocrine therapies led to a significant improvement in progression-free survival over standard therapy, with increased toxic effects, mainly neutropenia. (Funded by Pfizer and others; PATINA ClinicalTrials.gov number, NCT02947685.).

New England Journal of MedicineVol. 394(5)
Hebron University (PS), University of North Carolina Health Care (US), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), Garvan Institute of Medical Research (AU), Inserm (FR), Pfizer (United States) (US), Alliance for Clinical Trials in Oncology (US), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US), Peter MacCallum Cancer Centre (AU), Institut Gustave Roussy (FR), Yale University (US), Sorbonne Université (FR), Research Institute Hospital 12 de Octubre (ES), Alliance Foundation Trials (US), Instituto Oncológico Dr. Rosell (ES), Assistance Publique – Hôpitaux de Paris (FR), Fondazione Michelangelo (IT), Vall d'Hebron Institut de Recerca (ES), Centre Léon Bérard (FR), Auckland District Health Board (NZ), Dana-Farber Cancer Institute (US), Cancer Clinic (US), Vall d'Hebron Hospital Universitari (ES), German Breast group (DE), UniCancer Group (FR), Kliniken Essen-Mitte (DE), Hôpital Tenon (FR), Indiana University School of Medicine, Indiana University – Purdue University Indianapolis (US), University of Pennsylvania (US)
Good health and well-being
Openalex Percentile: Top 1%
Advanced Breast Cancer Therapies
36.44
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.